Protocol No
ALLOGENE-ALLO-715-101-RRMM
Principal Investigator
Meera Mohan
Phase
I
Summary
To test the safety of ALLO-715 in combination with ALLO-647 and to determine the safe dose of ALLO-715 following lymphodepletion with ALLO-647.
Description
Phase 1 Study of ALLO-715, an antiBCMA Allo CAR-T cell therapy for pt with rrMM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov